Airi Ishibashi
Overview
Explore the profile of Airi Ishibashi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
92
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ishibashi A, Li Y, Hisatomi Y, Ohta N, Uegaki Y, Tanemura A, et al.
Mol Ther Oncol
. 2024 Nov;
32(4):200893.
PMID: 39534532
The tumor-infiltrating lymphocyte (TIL) is a crucial factor in controlling tumor growth. A therapeutic method activating TIL is desired for treating patients with metastatic tumors. Here, we show that treating...
2.
Monitoring of cyanogenic compounds behavior during the manufacturing process of sweetened bean paste
Ito R, Kikuchi A, Ishibashi A, Kai T, Terashima A, Iwasaki Y, et al.
Heliyon
. 2024 Oct;
10(19):e38862.
PMID: 39435068
To ensure food safety, food business operators must eliminate or reduce hazardous factors in manufacturing processes by implementing effective process controls. Since some beans are known to contain cyanogenic compounds,...
3.
Nakatani A, Okumura R, Ishibashi A, Okamoto S, Sakaki K, Ito Y, et al.
Genes Cells
. 2023 Sep;
28(11):776-788.
PMID: 37680073
In the intestine, interleukin (IL)-23 and IL-22 from immune cells in the lamina propria contribute to maintenance of the gut epithelial barrier through the induction of antimicrobial production and the...
4.
Akiyama H, Ishibashi A, Kai T, Kikuchi A, Taguchi T, Fukiwake T, et al.
Biol Pharm Bull
. 2023 Jul;
46(7):1024-1026.
PMID: 37394634
It is necessary to evaluate the efficiency of reduction for cyanide and cyanoglycosides during the manufacturing process from raw material beans to sweetened bean paste in a food hygiene control...
5.
Taniguchi M, Okumura R, Matsuzaki T, Nakatani A, Sakaki K, Okamoto S, et al.
Mucosal Immunol
. 2023 Jun;
16(5):624-641.
PMID: 37385587
In the intestine, mucin 2 (Muc2) forms a network structure and prevents bacterial invasion. Glycans are indispensable for Muc2 barrier function. Among various glycosylation patterns of Muc2, sialylation inhibits bacteria-dependent...
6.
Ishibashi A, Saga K, Hisatomi Y, Li Y, Kaneda Y, Nimura K
Sci Rep
. 2020 Dec;
10(1):22345.
PMID: 33339985
CRISPR-Cas9 system can be used to generate knock-out cancer cell lines. An insertion or deletion induced by a single guide RNA (gRNA) is often used to generate knock-out cells, however,...
7.
Yoshikawa Y, Ishibashi A, Takehara T, Suzuki T, Murai K, Kaneda Y, et al.
ACS Med Chem Lett
. 2020 Jun;
11(6):1310-1315.
PMID: 32551017
We designed and synthesized a novel 1,2-deoxy-pyranose and terminal epoxide methyl substituted derivatives of spliceostatin A using Julia-Kocienski olefination as a key step. With respect to the biological activity, the...
8.
Saga K, Park J, Nimura K, Kawamura N, Ishibashi A, Nonomura N, et al.
J Exp Clin Cancer Res
. 2019 Oct;
38(1):416.
PMID: 31619256
Background: At the beginning of tumorigenesis, newly born cancer cells must successfully avoid attack by the immune system. Although most abnormal cells are efficiently identified and destroyed by the immune...
9.
Kawamura N, Nimura K, Saga K, Ishibashi A, Kitamura K, Nagano H, et al.
Cancer Res
. 2019 Aug;
79(20):5204-5217.
PMID: 31431456
Androgen receptor splice variant-7 (AR-V7) is a constitutively active AR variant implicated in castration-resistant prostate cancers. Here, we show that the RNA splicing factor SF3B2, identified by and CRISPR/Cas9 analyses,...